Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice

Journal of Experimental Therapeutics and Oncology

Volumn 8, Issue 1, 2009, Pages 43-51

  Shigama, Kota ^a   Nakaya, Akihiro ^a   Wakame, Koji ^a   Nishioka, Hiroshi ^a   Fujii, Hajime ^a  

^a Amino Up Chemical Co   (Japan)

Author keywords

Active hexose correlated compound (AHCC); Anticancer drug side effects; Hepatotoxicity; Mice; Mushroom extract; Myelosuppression; Nephrotoxicity

Indexed keywords

ACTIVE HEXOSE CORRELATED COMPOUND; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HEXOSE; IRINOTECAN; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DIET SUPPLEMENTATION; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; MONOTHERAPY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; WEIGHT CHANGE;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; BONE MARROW; CISPLATIN; FEMALE; KIDNEY; LIVER; MALE; MICE; PACLITAXEL; POLYSACCHARIDES;

EID: 70349122946     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Ajiki W, Tsukuma H, Oshima A. (2004). Cancer incidence and incidence rates in Japan in 1999: estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol, 34, 352-356. (Pubitemid 43115318)
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. (2008). Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. Jpn J Clin Oncol, 38, 641-648.
3. Pandey M, Sarita GP, Devi N, Thomas BC, Hussain BM, Krishnan R. (2006). Distress, anxiety, and depression in cancer patients undergoing chemotherapy. World J Surg Oncol, 4, 68-72. (Pubitemid 44541849)
4. Ciardiello F. (2000). Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs, 60, 25-32. (Pubitemid 30828935)
5. Baselga J, Averbuch SD. (2000). ZD1839 ('Iressa') as an aticancer agent. Drugs, 60, 33-40.
6. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ. (1999). Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther, 291, 739-748.
7. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. (2006). Dermatological side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol, 55, 657-670. (Pubitemid 44436627)
8. Sipples R. (2006). Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs, 22, 28-34.
9. Methvin AB, Gausas RE. (2007). Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg, 23, 63-65.
10. Astin JA. (1998). Why patients use alternative medicine: results of a national study. JAMA, 279, 1548-1553. (Pubitemid 28233010)
11. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. (1998). Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA, 280, 1569-1575. (Pubitemid 28520643)
12. Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T. (2000). Use of complementary/ alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol, 18, 2515-2521. (Pubitemid 30432516)
13. Mansky PJ, Wallerstedt DB. (2006). Complementary medicine in palliative care and cancer symptom management. Cancer J, 12, 425-431. (Pubitemid 44564825)
14. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S. (2005). Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol, 23, 2645-2654 (Pubitemid 46179453)
15. Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamano J, Takai S, Kwon AH, Kamiyama Y. (2008). Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a doubleblind, placebo-controlled trial. Nutr Cancer, 60, 643-651.
16. Belanger J. (2005). An in-office evaluation of four dietary supplements on natural killer cell activity. TOWNSEND LETTER, February/March, 88-92.
17. Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, Yin Z. (2005). Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother, 55, 1258-1266. (Pubitemid 43996648)
18. Matsushita K, Kuramitsu Y, Ohiro Y, Obata M, Kobayashi M, Li YQ, Hosokawa M. (1998). Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anti-cancer Drugs, 9, 343-350. (Pubitemid 28241824)
19. Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI. (2007). The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Phamacol, 222, 152-158. (Pubitemid 47094864)
20. Spierings ELH, Fujii H, Sun B, Walshe T. (2007). A phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. J Nutr Sci Vitaminol, 53, 536-539. (Pubitemid 351154876)
21. Mach CM, Fujii H, Wakame K, Smith J. (2008). Evaluation of active hexose correlated compound hepatic metabolism and potential for drug interactions with chemotherapy agents. J Soci Integr Oncol, 6, 105-109.
22. Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitada H, Imamura A, Takai S, Kawaguchi Y, Kwon AH, Kamiyama Y. (2002). Improved prognosis of postoperative hetatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol, 37, 78-86. (Pubitemid 34713058)
23. Cowawintaweewat S, Manoromana S, Sriplung H, Khuhaprema T, Tongtawe P, Tapchaisri P, Chaicumpa W. (2006). Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol, 24, 33-45. (Pubitemid 44044084)
24. Ritz BW. (2008). Supplementation with active hexose correlated compound increases survival following infectious challenge in mice. Nutr Rev, 66, 526-531.
25. Nicoletti MI, Lucchini V, D'Incalci M, Giavazzi R. (1994). Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur J Cancer, 30A, 691-696. (Pubitemid 24164262)
26. Fujimoto S, Chikazawa H. (1998). Schedule-dependent and independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo. Jpn J Cancer Res, 89, 1343-1351. (Pubitemid 29060570)
27. Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin M, Pendyala L, Zhang W, McLeod HL, Rustum YM. (2004). Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res, 10, 1121-1129. (Pubitemid 38198914)
28. Fujimoto S. (2006). Schedule-dependent antitumor activity and toxicity of combination of 5-fluorouracil and cisplatin/ carboplatin against L1210 leukemia-bearing mice. Biol. Pharm. Bull, 29, 2260-2266.
29. Braunschweiger PG, Schiffer LM. (1980). Cell kinetic-directed sequential chemotherapy with cyclophosphamide and adriamycin in T1699 mammary tumors. Cancer Res, 40, 737-743.
30. Masse M, Naegelen C, Pellegrini N, Segier JM, Marpaux N, Beaujean F. (1992). Validation of a simple method to count very low white cell concentrations in filtered red cells or platelets. Transfusion, 32, 565-571.
31. Sekine I, Nishiwaki Y, Watanabe K, Yoneda S, Saijo N. (1996). Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res, 2, 941-945. (Pubitemid 26198464)
32. Furuse K, Naka N, Takada M, Kinuwaki E, Kudo S, Takada Y, Yamakido M, Yamamoto H, Fukuoka M. (1997). Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. Oncology, 54, 298-303. (Pubitemid 27252725)
33. Bunn PA Jr. (1996). Combination paclitaxel and platinum in the treatment of lung cancer: US experience. Semin Oncol, 23, 9-15. (Pubitemid 27044331)
34. Chen CH, Chang JW, Lee CH, Tsao TC. (2005). Dose-finding and phase 2 study of weekly paclitaxel (taxol) and cisplatin combination in treating Chinese patients with advanced non-small cell lung cancer. Am J Clin Oncol, 28, 508-512. (Pubitemid 41437391)
35. Sandercock J, Parmar MK, Torri V. (1998). First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer, 78, 1471-1478. (Pubitemid 28517544)
36. Cunningham D. (1996). Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur J Cancer, 32A, S1-S8. (Pubitemid 126691397)
37. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser P, Ychou M, Elias D. (1994). Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer, 30A, 1263-1269. (Pubitemid 24322059)
38. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, Ito K. (2002). Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of portal vein. J Surg Oncol, 80, 143-148. (Pubitemid 34747619)
39. Kaern J, Tropé C, Sundfoer K, Kristensen GB. (1996). Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with longterm follow-up. Gynecol Oncol, 60, 387-392. (Pubitemid 26077622)
40. A'Hern RP, Smith IE, Ebbs SR. (1993). Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer, 67, 801-805.
41. Maschmeyer G, Haas A. (2008). The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents, 31, 193-197. (Pubitemid 351232171)
42. Groopman JE. (1990). Status of colony-stimulating factors in cancer and AIDS. Semin Oncol, 17, 31-37.
43. Dale DC. (2002). Colony-stimulating factors for the managementof neutropenia in cancer patients. Drugs, 62, 1-15.
44. Heuser M, Ganser A, Bokemeyer C. (2007). Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines. Semin Hematol, 44, 148-156. (Pubitemid 47031224)
45. Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, Sheridan W, Metcalf D, Fox R. (1988). Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet, 1, 667-672. (Pubitemid 18083268)
46. Kehoe S, Poole CJ, Stanley A, Earl HM, Blackledge GR. (1994). A phase I/II trial of recombinant human granulocytemacrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. Br J Cancer, 69, 537-540. (Pubitemid 24076475)
47. Merlano M, Benasso M, Numico GM, Danova M, Santelli A, Ameli F, Blengo F, Ricci I, Rosso M. (1998). 5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study. Am J Clin Oncol, 21, 313-316. (Pubitemid 28280150)
48. Azoulay E, Attalah H, Harf A, Schlemmer B, Delclaux C. (2001). Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Chest, 120, 1695-1701.
49. Takatsuka H, Takemoto Y, Mori A, Okamoto T, Kanamaru A, Kakishita E. (2002). Common features in the onset of ARDS after administration of granulocyte colony-stimulating factor. Chest, 121, 1716-1720. (Pubitemid 34499699)
50. Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K. (2007). Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood, 109, 3424-3431. (Pubitemid 46572532)
51. Hashimoto K, Suzuki I, Ohsawa M, Oikawa S, Yadomae T. (1990). Enhancement of hematopoietic response of mice by intraperitoneal administration of a beta-glucan, SSG, obtained from Sclerotinia sclerotiorum. J Pharmacobiodyn, 13, 512-517. (Pubitemid 20317189)
52. Patchen ML, Liang J, Vaudrain T, Martin T, Melican D, Zhong S, Stewart M, Quesenberry PJ. (1998). Mobilization of peripheral blood progenitor cells by betafectin PGG-glucan alone and in combination with granulocyte colony-stimulating factor. Stem Cells, 16, 208-217. (Pubitemid 28235165)
53. Patchen ML, Vaudrain T, Correira H, Martin T, Reese D. (1998). In vitro and in vivo hematopoietic activities of betafectin PGG-glucan. Exp. Hematol, 26, 1247-1254. (Pubitemid 28541768)
54. Lin H, She YH, Cassileth BR, Sirotnak F, Cunningham-Rundles S. (2004). Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro. Int Immunopharmacol, 4, 91-99. (Pubitemid 38223818)
55. Lin H, Cheung SWY, Nesin M, Cassileth BR, Cunningham-Rundles S. (2007). Enhancement of umbilical cord blood cell hematopoiesis by Maitake beta-glucan is mediated granulocyte colony-stimulating factor production. Clin Vaccine Immunol, 14, 21-27.
56. Tascilar M, de Jong FA, Verweij J, Mathijssen RH. (2006). Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist, 11, 732-741. (Pubitemid 44157561)
57. Seely D, Oneschuk D. (2008). Interactions of natural health products with biomedical cancer treatments. Curr Oncol, 15, S81-S86.
58. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. (2000). Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol, 18, 2505-2514. (Pubitemid 30432515)
59. Jazieh AR, Kopp M, Foraida M, Ghouse M, Khalil M, Savidge M, Sethuraman G. (2004). The use of dietary supplements by veterans with cancer. J Altern Complement Med, 10, 560-564. (Pubitemid 38879944)
60. Correa-Velez I, Clavarino A, Eastwood H. (2005). Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis. J Palliat Med, 8, 953-961. (Pubitemid 41579237)